CARsgen Therapeutics completes enrollment in Phase II trial of Satri-cel for advanced gastric cancer
CARsgen Therapeutics Holdings Limited, a prominent player in the field of CAR T-cell therapies, has announced the successful completion of patient enrollment for its pivotal ... Read More
Vimgreen Pharmaceuticals progresses with Phase 2 trial of VG081821AC for Parkinson’s disease
Vimgreen Pharmaceuticals has marked a significant milestone with the completion of participant enrollment in its Phase 2 clinical trial for VG081821AC, a cutting-edge treatment for ... Read More
Roche reports setback in lung cancer study with tiragolumab and tecentriq combination
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced disappointing results from the phase II/III SKYSCRAPER-06 study, aimed at evaluating the efficacy of tiragolumab plus Tecentriq ... Read More
Dynavax begins clinical trial for new shingles vaccine candidate, Z-1018
Dynavax Technologies Corporation, a renowned player in the biopharmaceutical sector, has made headlines with the initiation of a Phase 1/2 clinical trial for its innovative ... Read More
Indivior initiates Phase 2 study for INDV-2000, targeting opioid use disorder with non-opioid treatment
Indivior PLC (LSE/Nasdaq: INDV) has announced the commencement of a Phase 2 clinical trial involving INDV-2000, a non-opioid treatment, marking a significant advancement in the ... Read More
Oxford BioDynamics collaborates with National Cancer Institute in prostate cancer clinical trial
Oxford BioDynamics Plc (AIM: OBD), a pioneering biotechnology company, has announced its participation in a significant clinical trial led by the National Cancer Institute (NCI) ... Read More
Kodiak Sciences advances Phase 3 study of tarcocimab tedromer in diabetic retinopathy
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that the first patients with diabetic retinopathy have ... Read More
FDA approves Italfarmaco’s Duvyzat for duchenne muscular dystrophy treatment
In a significant advancement for the treatment of Duchenne muscular dystrophy (DMD), Italfarmaco S.p.A. has announced the U.S. Food and Drug Administration (FDA) approval of ... Read More
Xeris Pharmaceuticals begins Phase 2 trial for glucagon in Type 1 diabetes patients
Xeris Pharmaceuticals, a specialty pharmaceutical company based in Chicago, has announced the commencement of dosing in its phase 2 clinical trial. The trial aims to ... Read More
Biohaven secures orphan drug status for verdiperstat in MSA treatment
Connecticut-based Biohaven Pharmaceutical has received a significant regulatory boost, with the US FDA granting orphan drug designation for its investigational drug verdiperstat for treating multiple ... Read More